GlassScriptPhysician profile
Vivekanand Jain
NPI 1952456352
$7,745.64
in general payments reported to CMS, 2019-2025
34 companies · $770 in 2025
The $770 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $1,153 · 2021: $1,533 · 2022: $1,074 · 2023: $983 · 2024: $937 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,690.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,290.44 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $815.38 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $808.08 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $731.49 | 2019-2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $616.59 | 2019-2024 | Xifaxan |
| Pfizer INC. | $537.42 | 2019-2024 | |
| Novo Nordisk INC | $238.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $214.45 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $207.07 | 2019-2020 | |
| Astellas Pharma US INC | $129.11 | 2020-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $126.78 | 2020-2022 | |
| Amgen INC. | $116.72 | 2019-2025 | Repatha, Otezla, Otezla |
| Biohaven Pharmaceuticals, INC. | $104.67 | 2021 | |
| Exact Sciences Corporation | $87.33 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $80.25 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $76.55 | 2020-2022 | |
| Therapeuticsmd, INC. | $72.30 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $56.75 | 2019-2023 | Verquvo, Januvia, Belsomra |
| Acorda Therapeutics, INC | $53.03 | 2022-2023 | Inbrija |
| Arbor Pharmaceuticals, INC. | $47.33 | 2021 | |
| Edwards Lifesciences Corporation | $46.61 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Oxford Immunotec USA INC | $30.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.86 | 2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $25.44 | 2022 | |
| Theratechnologies INC. | $24.44 | 2025 | Egrifta, Trogarzo |
| Amarin Pharma, INC. | $23.79 | 2020 | |
| Sumitomo Pharma America, INC. | $23.54 | 2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $22.90 | 2024 | Voquezna |
| Abbott Laboratories | $22.70 | 2022 | |
| Biogen, INC. | $20.83 | 2021 | |
| Alfasigma USA, INC. | $19.29 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.19 | 2024 | Nuzyra |
| Nestle Healthcare Nutrition INC. | $15.29 | 2023 | |
| Allergan, INC. | $14.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivekanand Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.